{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:56:28Z","timestamp":1783115788274,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["EPCD0000008"],"award-info":[{"award-number":["EPCD0000008"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2009389"],"award-info":[{"award-number":["GNT2009389"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.107011","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:26:05Z","timestamp":1768494365000},"page":"107011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Polypharmacy prevalence, associated factors, and changes over time in Australians with multiple sclerosis"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-1930","authenticated-orcid":false,"given":"Ting","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnat","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huah Shin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Laslett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"van der Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107011_bib0029","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/1817-1737.109823","article-title":"Does the patients' educational level and previous counseling affect their medication knowledge?","volume":"8","author":"Alkatheri","year":"2013","journal-title":"Ann. Thorac. Med."},{"issue":"20-25","key":"10.1016\/j.msard.2026.107011_bib0019","article-title":"A systematic review of the validity and reliability of the patient-determined disease steps scale","volume":"25","author":"Ann Marrie","year":"2023","journal-title":"Int. J. MS. Care"},{"key":"10.1016\/j.msard.2026.107011_bib0017","series-title":"The Fourth Australian Atlas of Healthcare Variation","year":"2021"},{"key":"10.1016\/j.msard.2026.107011_bib0012","unstructured":"Australian Commission on Safety and Quality in Health Care, https:\/\/www.safetyandquality.gov.au\/our-work\/medication-safety\/who-global-patient-safety-challenge-medication-without-harm."},{"key":"10.1016\/j.msard.2026.107011_bib0015","unstructured":"Australian MS Longitudinal Study, https:\/\/www.msaustralia.org.au\/amsls\/."},{"key":"10.1016\/j.msard.2026.107011_bib0002","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/13524585241265890","article-title":"Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021","volume":"30","author":"Campbell","year":"2024","journal-title":"Multip. Scler. J."},{"key":"10.1016\/j.msard.2026.107011_bib0014","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11910-023-01289-9","article-title":"Polypharmacy in multiple sclerosis: prevalence, risks, and mitigation strategies","volume":"23","author":"Chapman","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2026.107011_bib0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40266-016-0357-2","article-title":"Pharmacist-led home medicines review and residential medication management review: the Australian model","volume":"33","author":"Chen","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.msard.2026.107011_bib0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/13524585221122207","article-title":"Polypharmacy and multiple sclerosis: a population-based study","volume":"29","author":"Chertcoff","year":"2023","journal-title":"Multip. Scler. J."},{"key":"10.1016\/j.msard.2026.107011_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse outcomes of polypharmacy in older people: systematic review of reviews","volume":"21","author":"Davies","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.msard.2026.107011_bib0008","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/pds.4207","article-title":"Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations","volume":"26","author":"Evans","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.msard.2026.107011_bib0024","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14740338.2020.1720646","article-title":"Polypharmacy among patients with multiple sclerosis: a qualitative systematic review","volume":"19","author":"Frahm","year":"2020","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.msard.2026.107011_bib0004","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.therap.2019.10.001","article-title":"Polypharmacy: a general review of definitions, descriptions and determinants","volume":"75","author":"Guillot","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.msard.2026.107011_bib0003","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"10.1016\/j.msard.2026.107011_bib0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healthpol.2012.09.005","article-title":"The impact of increasing polypharmacy on prescribed drug expenditure\u2014a register-based study in Sweden 2005\u20132009","volume":"109","author":"Hovstadius","year":"2013","journal-title":"Health Policy. (New. York)"},{"key":"10.1016\/j.msard.2026.107011_bib0022","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1179\/1743132815Y.0000000036","article-title":"Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability","volume":"37","author":"Jelinek","year":"2015","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2026.107011_bib0026","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.sapharm.2015.06.007","article-title":"Clinical medication review in Australia: a systematic review","volume":"12","author":"Jokanovic","year":"2016","journal-title":"Res. Soc. Administr. Pharm."},{"key":"10.1016\/j.msard.2026.107011_bib0020","article-title":"Trends of polypharmacy among older people in Asia, Australia and the United Kingdom: a multinational population-based study","volume":"52","author":"Lee","year":"2023","journal-title":"Age Age."},{"key":"10.1016\/j.msard.2026.107011_bib0013","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1111\/ene.14887","article-title":"Comorbidity patterns in people with multiple sclerosis: a latent class analysis of the Australian Multiple Sclerosis Longitudinal Study","volume":"28","author":"Lo","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107011_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.msard.2026.107011_bib0016","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res. Note."},{"key":"10.1016\/j.msard.2026.107011_bib0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000368191","article-title":"Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005\u20132013","volume":"61","author":"Nishtala","year":"2015","journal-title":"Gerontology"},{"key":"10.1016\/j.msard.2026.107011_bib0027","series-title":"Guidelines for Comprehensive Medication Management Reviews","author":"PSo","year":"2020"},{"key":"10.1016\/j.msard.2026.107011_bib0028","article-title":"Influence of education level of older patients on polypharmacy, potentially inappropriate medications listed in beer's criteria, and unplanned hospitalization: a cross-sectional study in Lahore, Pakistan","volume":"54","author":"Sarwar","year":"2018","journal-title":"Medic. (Kaunas)"},{"key":"10.1016\/j.msard.2026.107011_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11606-019-04837-7","article-title":"Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness","volume":"34","author":"Schenker","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.msard.2026.107011_bib0021","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jpsychores.2014.02.013","article-title":"Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance","volume":"76","author":"Thelen","year":"2014","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.msard.2026.107011_bib0011","first-page":"239","article-title":"Polypharmacy in multiple sclerosis: current knowledge and future directions","volume":"118","author":"Thelen","year":"2021","journal-title":"Mo Med."},{"key":"10.1016\/j.msard.2026.107011_bib0018","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1467-842X.2005.tb00224.x","article-title":"The Index of Relative Socio-economic Disadvantage: general population views on indicators used to determine area-based disadvantage","volume":"29","author":"Walker","year":"2005","journal-title":"Aust. N.Z. J. Public Health"},{"key":"10.1016\/j.msard.2026.107011_bib0001","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Multip. Scler. J."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:49:22Z","timestamp":1780415362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"alternative-id":["S2211034826000477"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107011","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacy prevalence, associated factors, and changes over time in Australians with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107011"}}